What is the incretin system, and why does it matter for weight loss?
When you eat, your gut releases hormones that signal to the pancreas, liver, and brain. These hormones — called incretins — regulate insulin secretion, glucagon suppression, gastric emptying, and satiety. Two incretins are central to tirzepatide’s mechanism: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
GLP-1 is secreted by intestinal L-cells in response to nutrient intake. It stimulates insulin release from pancreatic beta cells, suppresses glucagon from alpha cells (reducing hepatic glucose output), slows gastric emptying so nutrients enter the bloodstream more gradually, and signals satiety to the hypothalamus. Its short half-life in the body means the native hormone’s effects are brief; GLP-1 receptor agonists extend those effects pharmacologically.
GIP is secreted by duodenal K-cells, also in response to nutrient intake. Historically, it was considered primarily a pancreatic insulin secretagogue, but more recent research has revealed GIP receptors in the brain — particularly in hypothalamic regions involved in appetite regulation — and in adipose tissue, where GIP influences fat metabolism.
What is tirzepatide’s dual mechanism?
Tirzepatide is a single synthetic peptide molecule engineered to be a dual agonist — it binds and activates both the GIP receptor and the GLP-1 receptor. This is what distinguishes it from semaglutide and other GLP-1 agonists, which target only the GLP-1 receptor.
The molecule is based on the native GIP peptide sequence, modified for longer half-life and balanced affinity for both receptors. In clinical testing, it demonstrates roughly equivalent potency at the GIP receptor and slightly lower potency at the GLP-1 receptor compared to selective agonists — but the combined effect on appetite, satiety, and metabolic regulation appears additive or synergistic rather than simply equal to the sum of its parts.
GLP-1 receptor activation
At the GLP-1 receptor, tirzepatide drives the same effects as GLP-1 agonists like semaglutide:
- Glucose-dependent insulin secretion from beta cells
- Glucagon suppression from alpha cells
- Delayed gastric emptying (slowing the delivery of nutrients from the stomach)
- Hypothalamic satiety signaling, reducing appetite
GIP receptor activation
The GIP component adds a distinct layer:
- Additional hypothalamic signaling through GIP receptors co-expressed with GLP-1 receptors in appetite-regulatory circuits
- Adipocyte effects that appear to influence fat storage and mobilization independently of the pancreatic channel
- Evidence in preclinical and early clinical work suggests GIP agonism may amplify the GLP-1-mediated satiety signal rather than duplicating it
The net effect: greater appetite reduction and, in trials, greater average weight loss than single GLP-1 agonists at comparable dose levels.
Tirzepatide is the first weight-management drug to hit two incretin receptors at once — GLP-1 and GIP — and that dual signaling is what sets it apart.
What do clinical trials show about tirzepatide weight loss results?
The SURMOUNT-1 trial — a pivotal Phase 3 randomized controlled trial — tested tirzepatide in adults with obesity (BMI ≥30) or overweight with at least one weight-related comorbidity, without type 2 diabetes. Participants received tirzepatide 5 mg, 10 mg, or 15 mg weekly, or placebo, for 72 weeks, with lifestyle intervention in all groups.
The 72-week results showed average weight reductions of:
| Group | Weekly Dose | Avg. Weight Reduction at 72 Weeks |
|---|---|---|
| Placebo | — | ~2.4% |
| Tirzepatide | 5 mg | ~15.0% |
| Tirzepatide | 10 mg | ~19.5% |
| Tirzepatide | 15 mg | ~20.9% |
Source: SURMOUNT-1 (Jastreboff AM et al., NEJM 2022). All groups received lifestyle intervention. Results are population averages; individual outcomes vary.
In a separate head-to-head comparison against semaglutide (SURPASS-2, in patients with type 2 diabetes), tirzepatide at all three doses produced greater reductions in body weight than semaglutide 1 mg weekly. The SURMOUNT program did not directly compare tirzepatide to semaglutide 2.4 mg in a controlled head-to-head trial for weight management specifically, but indirect comparisons and real-world observations are consistent with a tirzepatide advantage in average weight reduction.
Individual response varies considerably. Some patients are strong responders at lower doses; others need higher doses for meaningful effect. Some patients plateau earlier than the trial averages.
What does the gastric emptying effect mean for you?
Delayed gastric emptying is one of the primary mechanisms behind GLP-1 and GIP agonist-driven satiety and it has practical implications beyond weight management:
- Nausea and GI side effects: The most common side effects of tirzepatide (nausea, vomiting, diarrhea, constipation) are largely consequences of delayed gastric emptying and altered gut motility. These effects are most pronounced early in therapy and during dose increases, and typically improve over weeks as the GI tract adapts.
- Surgical and anesthesia planning: Delayed gastric emptying persists while the drug is active, raising aspiration risk with general anesthesia. Current anesthesiology guidance recommends pausing weekly GLP-1/GIP agonists before elective procedures. Patients on tirzepatide should inform their surgical and anesthesia team.
- Oral medication absorption: Delayed gastric emptying can affect the absorption rate of orally administered medications. Patients on time-sensitive oral medications (certain diabetes medications, thyroid hormone, oral contraceptives) should discuss timing and absorption considerations with their prescribing clinician.
What is compounded tirzepatide — and what is it not?
Compounded tirzepatide is prepared by licensed 503A compounding pharmacies using pharmaceutical-grade tirzepatide base. It is a separate preparation from branded Mounjaro (indicated for type 2 diabetes) and Zepbound (indicated for weight management in adults meeting BMI criteria), which are FDA-approved products with specific formulations and delivery devices.
Compounded tirzepatide is not FDA-approved. No compounded drug product is. The 503A compounding framework allows licensed pharmacies to prepare customized formulations — including dose concentrations not available in standard branded devices — under physician prescription and appropriate pharmacy oversight. PepScribe’s compounded tirzepatide is prepared in the USA by licensed 503A pharmacies. No hidden overseas supply chain.
The mechanism of action is the same dual GIP/GLP-1 agonism — it is the same peptide sequence. But it is not the same product, and clinicians and patients should understand the regulatory distinction.
Who is a candidate, and what does a clinician evaluation involve?
Tirzepatide therapy requires a licensed clinician evaluation that screens for contraindications, establishes a clinical indication, and designs an appropriate titration protocol. Key contraindications include:
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- History of pancreatitis
- Severe renal or hepatic impairment
- Pregnancy or active plans to conceive
The clinician also reviews concurrent medications — particularly other glucose-lowering agents — and designs a titration schedule appropriate for the patient’s GI tolerance, goals, and clinical baseline. Protocol decisions (starting dose, step size, ceiling dose, maintenance schedule) are individualized.
Frequently asked questions
How does tirzepatide work for weight loss?
Tirzepatide activates two incretin hormone receptors — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This dual agonism reduces appetite through hypothalamic signaling, slows gastric emptying so meals feel more filling, and improves insulin sensitivity and metabolic regulation. The combination produces more pronounced weight reduction in trials than single GLP-1 agonists at comparable doses.
How is tirzepatide different from semaglutide for weight loss?
Semaglutide is a GLP-1 receptor agonist only. Tirzepatide adds GIP receptor agonism. GIP receptors are found in the brain and adipose tissue; their activation appears to amplify the GLP-1-mediated satiety signal and may directly affect fat metabolism. Clinical trials suggest tirzepatide produces greater average weight reduction than semaglutide at studied doses, though individual responses vary.
Is tirzepatide FDA approved?
Tirzepatide is FDA-approved under the brand name Mounjaro for type 2 diabetes and under Zepbound for weight management. Compounded tirzepatide — a separate preparation made by licensed 503A pharmacies — is not FDA-approved and is not the same product as Mounjaro or Zepbound.
How long does it take tirzepatide to work for weight loss?
Appetite suppression often begins within the first 1–2 weeks. Meaningful weight changes typically become apparent at 4–8 weeks, with the full trajectory of loss extending over months. SURMOUNT-1 showed average weight reductions of 15–20% at 72 weeks at the highest doses, but individual response varies substantially.
Does tirzepatide work without diet and exercise?
Trials include lifestyle intervention alongside tirzepatide, so the drug's effect in isolation is not perfectly separated. However, the magnitude of weight reduction in clinical trials is substantially larger than lifestyle-alone comparisons, indicating a strong pharmacological effect. Clinicians recommend combining tirzepatide with dietary and activity support for durable outcomes.
What happens to weight when tirzepatide is stopped?
Published follow-up studies consistently show substantial weight regain after discontinuation — most of the lost weight returns within one to two years. This reflects the underlying biology: tirzepatide addresses appetite and metabolic dysregulation while it's active but doesn't correct the root cause. Long-term or maintenance dosing is often clinically appropriate.